OPKO Health (NASDAQ:OPK) CEO Phillip Md Et Al Frost Buys 580,000 Shares of Stock

OPKO Health, Inc. (NASDAQ:OPK) CEO Phillip Md Et Al Frost bought 580,000 shares of OPKO Health stock in a transaction on Wednesday, November 19th. The shares were purchased at an average cost of $1.31 per share, for a total transaction of $759,800.00. Following the completion of the purchase, the chief executive officer directly owned 215,546,448 shares of the company’s stock, valued at $282,365,846.88. This trade represents a 0.27% increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is available at this link.

Phillip Md Et Al Frost also recently made the following trade(s):

• On Tuesday, November 18th, Phillip Md Et Al Frost purchased 533,300 shares of OPKO Health stock. The shares were purchased at an average price of $1.27 per share, with a total value of $677,291.00.
• On Friday, October 31st, Phillip Md Et Al Frost purchased 150,000 shares of OPKO Health stock. The shares were purchased at an average cost of $1.42 per share, for a total transaction of $213,000.00.

OPKO Health Trading Up 2.3%

Shares of OPKO Health stock opened at $1.31 on Thursday. The stock has a 50 day moving average of $1.44 and a 200 day moving average of $1.37. The company has a debt-to-equity ratio of 0.25, a quick ratio of 3.02 and a current ratio of 3.41. The firm has a market capitalization of $1.01 billion, a price-to-earnings ratio of -5.24 and a beta of 1.50. OPKO Health, Inc. has a fifty-two week low of $1.11 and a fifty-two week high of $2.04.

OPKO Health (NASDAQ:OPK) last announced its quarterly earnings results on Wednesday, October 29th. The biotechnology company reported $0.03 EPS for the quarter, beating the consensus estimate of ($0.02) by $0.05. The business had revenue of $151.67 million for the quarter, compared to analyst estimates of $165.74 million. OPKO Health had a negative return on equity of 13.62% and a negative net margin of 28.10%.The company’s quarterly revenue was down 12.6% on a year-over-year basis. During the same quarter in the prior year, the company posted $0.03 EPS. As a group, research analysts predict that OPKO Health, Inc. will post -0.25 earnings per share for the current year.

Institutional Investors Weigh In On OPKO Health

A number of hedge funds and other institutional investors have recently modified their holdings of OPK. Oak Thistle LLC purchased a new position in OPKO Health in the first quarter valued at $26,000. Caprock Group LLC purchased a new position in shares of OPKO Health in the 3rd quarter valued at about $26,000. GM Advisory Group LLC acquired a new stake in shares of OPKO Health during the 1st quarter worth about $33,000. Savant Capital LLC acquired a new position in OPKO Health in the third quarter valued at approximately $33,000. Finally, Cerity Partners LLC purchased a new position in OPKO Health in the first quarter valued at approximately $36,000. 64.63% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

OPK has been the topic of a number of research analyst reports. Wall Street Zen raised shares of OPKO Health from a “strong sell” rating to a “hold” rating in a research note on Saturday, November 1st. Barrington Research reissued an “outperform” rating and issued a $2.25 target price on shares of OPKO Health in a research report on Thursday, October 30th. Weiss Ratings restated a “sell (d-)” rating on shares of OPKO Health in a research report on Wednesday, October 8th. Zacks Research upgraded OPKO Health from a “strong sell” rating to a “hold” rating in a report on Thursday, August 14th. Finally, Jefferies Financial Group reissued a “hold” rating and set a $1.60 target price (down previously from $2.00) on shares of OPKO Health in a research note on Thursday, October 30th. One analyst has rated the stock with a Strong Buy rating, two have given a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Hold” and a consensus target price of $2.28.

OPKO Health Company Profile

OPKO Health, Inc, a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers, and governmental units; and 4Kscore prostate cancer test.